Pfizer Shares Owned by Insiders

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Report: 28th of July 2020  

Pfizer shares owned by insiders fundamental analysis lookup allows you to check this and other indicators for Pfizer Inc or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Shares Owned by Insiders

Pfizer Weighted Average Shares Diluted is expected to decrease significantly based on the last few years of reporting. The past year's Weighted Average Shares Diluted was at 5.67 Billion.

Pfizer Shares Owned by Insiders Analysis

Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

  Pfizer Profit Margin

Insiders Shares 
Executives Shares 
More About Shares Owned by Insiders | All Equity Analysis

Current Pfizer Inc Shares Owned by Insiders

0.04 %

Pfizer Distress Driver Correlations

About Shares Owned by Insiders

Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Compare to competition

  Accumulated Other Comprehensive Income

Based on the latest financial disclosure 0.04% of Pfizer Inc are shares owned by insiders. This is 99.74% lower than that of the Healthcare sector, and significantly higher than that of Drug Manufacturers?General industry, The Shares Owned by Insiders for all stocks is 99.6% higher than the company.

Pfizer Shares Owned by Insiders Peer Comparison

  Shares Owned by Insiders 
      Pfizer Comparables 
Pfizer is rated below average in shares owned by insiders category among related companies.

PfizerCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee633.52 K498.99 K545.9 K582.55 K580.6 K586.07 K655.69 K
Average Assets170.84 B164.94 B170.91 B170.32 B164.21 B162.39 B158.48 B
Earnings before Tax12.26 B8.95 B8.34 B12.26 B11.86 B17.66 B17.1 B
Average Equity75.92 B66.44 B62.17 B62.22 B68.67 B61.66 B63.18 B
Enterprise Value230.88 B235.06 B239.08 B257.07 B289.8 B266.7 B273.97 B
Free Cash Flow15.5 B13.19 B14.19 B14.59 B13.63 B9.99 B11.24 B
Invested Capital102.08 B84.64 B72.89 B78.83 B79.54 B87.01 B84.82 B
Tangible Asset Value90.33 B78.78 B64.52 B67.1 B70.8 B73.47 B73.9 B
Working Capital34.01 B14.4 B7.83 B10.71 B18.07 B(4.5 B)(4.62 B)
Interest Coverage13.7813.012.4214.6111.787.679.09
Calculated Tax Rate25.4922.213.45(73.539212)5.947.839.52
PPandE Turnover4.113.833.893.873.943.783.59
Receivables Turnover5.55.86.426.396.66.185.59
Inventory Turnover1.621.461.721.571.491.291.59
Operating Margin25.9819.3716.8424.4421.5819.9719.72
Return on Investment11.678.948.6711.8710.539.3811.02
Cash Flow Per Share2.682.352.622.752.772.272.24
Quick Ratio1.792.071.070.840.930.50.51
Book Value per Share11.2410.489.7811.9410.811.3410.64
Current Ratio2.671.491.251.351.570.880.9
Debt to Equity Ratio0.510.60.710.610.660.830.68
EBITDA Margin34.727.4724.8434.1533.1145.6837.74

Pfizer Institutional Holders

Current Institutional Investors

Security TypeSharesValue
Confluence Investment Management LlcCommon Shares2.3 M76.1 M
Park National CorpCommon Shares470.4 K15.4 M
First Financial BanCommon Shares201 K6.6 M
Pensionfund Dsm NetherlandsCommon Shares150.8 K4.9 M
Pensionfund SabicCommon Shares109.1 K3.6 M
Thomasville National BankCommon Shares88.2 K2.9 M
Boltwood Capital ManagementCommon Shares73.6 K2.4 M

Pfizer Fundamentals

About Pfizer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables8.22 B8.03 B8.72 B10.38 B
Inventories7.58 B7.51 B8.28 B7.42 B

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page